Breakthrough T1D – Development of continuous C-Peptide monitoring technologies

Objectives:

Examples of research appropriate for this RFA include, but are not limited to:

• Early-stage development of sensor technologies capable of continuous or high-frequency C-Peptide detection in biological fluids such as plasma or interstitial fluid
• Preclinical development and validation of CCPM systems
• Feasibility studies and early-stage clinical evaluation of CCPM technologies

Proposals must define clear, realistic goals and milestones aligned with the maturity of the technology. Proposals must be designed to reach key inflection points that will determine whether further development is warranted. Examples include:

• In vitro characterization of sensor performance (e.g., sensitivity, specificity, stability, dynamic range)
• Demonstration of detection in relevant biological fluids under physiological conditions
• Initial validation in animal models or early clinical feasibility studies
• Integration of biosensors into user-friendly, wearable, or at-home platforms

Eligibility:

• Applications must be submitted by domestic and foreign non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of state and local government and eligible agencies of the federal government
• Applicants must hold a M.D., D.O., D.M.D., D.V.M., PhD or equivalent and have a faculty position or equivalent at a college, university, medical school or other research facility
• To assure continued excellence and diversity among applicants and awardees, Breakthrough T1D welcomes proposals from all qualifies individuals and encourages proposals from a broad cross section of researchers and scientists

Applications may request up to a total of USD 900.000 for up to three years.

LOI by December 4th 2025

Full proposal deadline: Februrary 12th 2025